These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9517505)
1. Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity. Thomas X; Anglaret B; Adeleine P; Maritaz O; Bailly M; Fiere D; Archimbaud E Leuk Lymphoma; 1998 Jan; 28(3-4):343-53. PubMed ID: 9517505 [TBL] [Abstract][Full Text] [Related]
2. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1. Triozzi PL; Eicher DM; Smoot J; Rinehart JJ Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453 [TBL] [Abstract][Full Text] [Related]
3. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG. Komatsu F; Kajiwara M Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342 [TBL] [Abstract][Full Text] [Related]
4. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity. Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379 [TBL] [Abstract][Full Text] [Related]
5. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Bendall LJ; Kortlepel K; Gottlieb DJ Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403 [TBL] [Abstract][Full Text] [Related]
6. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance. Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919 [TBL] [Abstract][Full Text] [Related]
7. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. Teichmann JV; Ludwig WD; Thiel E Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316 [TBL] [Abstract][Full Text] [Related]
8. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Komatsu F; Kajiwara M Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151 [TBL] [Abstract][Full Text] [Related]
9. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells. Fujiwara T; Loudon WG; Grimm EA Lymphokine Cytokine Res; 1993 Feb; 12(1):45-8. PubMed ID: 8096153 [TBL] [Abstract][Full Text] [Related]
10. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells. Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670 [TBL] [Abstract][Full Text] [Related]
12. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells. Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482 [TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Chao TY; Jiang SY; Shyu RY; Yeh MY; Chu TM Br J Cancer; 1997; 75(9):1284-90. PubMed ID: 9155047 [TBL] [Abstract][Full Text] [Related]
15. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis. Lefor AT; Rosenberg SA J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427 [TBL] [Abstract][Full Text] [Related]
16. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays. Tzeng JJ; Barth RF J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514 [TBL] [Abstract][Full Text] [Related]
18. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface. Komatsu F; Kajiwara M Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061 [TBL] [Abstract][Full Text] [Related]
19. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
20. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants. Gross N; Favre S; Beck D; Meyer M Int J Cancer; 1992 Aug; 52(1):85-91. PubMed ID: 1354203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]